Core Viewpoint - Aardvark Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant stock price drop due to the voluntary pause of its Phase 3 HERO trial [1][3]. Group 1: Company Actions - On February 27, 2026, Aardvark announced the voluntary pause of the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial due to reversible cardiac observations at above target therapeutic doses found during routine safety monitoring [3]. - The company is conducting a comprehensive review of the data to inform next steps regarding the HERO trial [3]. Group 2: Market Reaction - Following the announcement of the trial pause, Aardvark's stock price fell by $7.02 per share, representing a 56.2% decrease, closing at $5.47 per share on March 2, 2026 [3]. Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Aardvark investors regarding potential securities fraud or other unlawful business practices by the company and its officers and/or directors [1].